S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Rubius Therapeutics (RUBY) Stock Forecast, Price & News

-0.07 (-6.48%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
764,500 shs
Average Volume
1.20 million shs
Market Capitalization
$91.12 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for Rubius Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Rubius Therapeutics logo

About Rubius Therapeutics

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.


What 6 Analyst Ratings Have To Say About Rubius Therapeutics
Rubius Therapeutics up 34% after insider buy
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.49 per share


Net Income
$-196.55 million
Pretax Margin




Free Float
Market Cap
$91.12 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.67 out of 5 stars

Medical Sector

71st out of 1,416 stocks

Biological Products, Except Diagnostic Industry

7th out of 210 stocks

Analyst Opinion: 3.3Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 1.3 5 -4 -3 -2 -1 -

Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

Is Rubius Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rubius Therapeutics stock.
View analyst ratings for Rubius Therapeutics
or view top-rated stocks.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Rubius Therapeutics

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) issued its earnings results on Tuesday, May, 10th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.57) by $0.01. During the same period in the previous year, the company posted ($0.51) EPS.
View Rubius Therapeutics' earnings history

What price target have analysts set for RUBY?

4 analysts have issued 1-year price targets for Rubius Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they anticipate Rubius Therapeutics' share price to reach $5.00 in the next twelve months. This suggests a possible upside of 395.0% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Rubius Therapeutics' key executives?
Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein B.Sc., M.B.A., Exec. Chairman (Age 60, Pay $495k)
  • Dr. Pablo J. Cagnoni M.D., Ph.D., CEO, Pres & Director (Age 59, Pay $971.45k) (LinkedIn Profile)
  • Mr. Jose I. Carmona, CFO, Principal Accounting Officer & Treasurer (Age 50, Pay $659.2k)
  • Ms. Dannielle Appelhans, Chief Operating Officer (Age 39, Pay $422.98k)
  • Mr. Laurence A. Turka M.D., Chief Scientific Officer and Head of Research & Translational Medicine (Age 64, Pay $626.55k)
  • Ms. Maiken Keson-Brookes, Chief Legal Officer & Corp. Sec. (Age 49, Pay $607.74k) (LinkedIn Profile)
  • Mr. Spencer Fisk, Sr. VP & Chief Technical Operations Officer
  • Mr. Mark J. Hernon, Chief Information Officer (Age 58)
  • Ms. Lori Melancon, Chief Corp. Affairs Officer
  • Ms. Marissa Hanify, Director of Corp. Communications
What is Pablo Cagnoni's approval rating as Rubius Therapeutics' CEO?

12 employees have rated Rubius Therapeutics CEO Pablo Cagnoni on Glassdoor.com. Pablo Cagnoni has an approval rating of 91% among Rubius Therapeutics' employees. This puts Pablo Cagnoni in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Rubius Therapeutics own?
When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (5.44%), BlackRock Inc. (3.89%), JPMorgan Chase & Co. (3.40%), Victory Capital Management Inc. (3.25%), Vanguard Group Inc. (2.58%) and State Street Corp (1.10%). Company insiders that own Rubius Therapeutics stock include David R Epstein, Maiken Keson-Brookes, Pablo J Cagnoni and Ventures Fund Iv Gene Flagship.
View institutional ownership trends for Rubius Therapeutics

Which institutional investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Citigroup Inc., JPMorgan Chase & Co., Baillie Gifford & Co., Northern Trust Corp, Goldman Sachs Group Inc., and Charles Schwab Investment Management Inc.. Company insiders that have sold Rubius Therapeutics company stock in the last year include Maiken Keson-Brookes, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Rubius Therapeutics stock?

RUBY stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State of Michigan Retirement System, Maven Securities LTD, IndexIQ Advisors LLC, Los Angeles Capital Management LLC, Connor Clark & Lunn Investment Management Ltd., Renaissance Technologies LLC, and Nisa Investment Advisors LLC. Company insiders that have bought Rubius Therapeutics stock in the last two years include David R Epstein, and Ventures Fund Iv Gene Flagship.
View insider buying and selling activity for Rubius Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $1.01.

How much money does Rubius Therapeutics make?

Rubius Therapeutics has a market capitalization of $91.12 million. The company earns $-196.55 million in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Rubius Therapeutics have?

Rubius Therapeutics employs 269 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 679-9600 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.